Choong ANG Vaccine Laboratory
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Choong ANG Vaccine Laboratory makes vaccines and biological medicines that protect livestock and companion animals from infectious diseases.
Its products are used by livestock farmers and veterinary professionals across South Korea, and it is listed on KOSDAQ, Korea's small-cap and technology exchange. The company's core business is concentrated in biological preparations, vaccines in particular, rather than conventional antibiotic treatments, reflecting a broader industry shift from treating disease to preventing it.
Summary is AI-generated and may contain errors · figures from DART filings
Choong ANG Vaccine Laboratory in five facts
What does Choong ANG Vaccine Laboratory do?
Choong ANG Vaccine Laboratory makes vaccines and biological medicines that protect livestock and companion animals from infectious diseases.
Where is Choong ANG Vaccine Laboratory listed and in which sector?
Choong ANG Vaccine Laboratory (Korean name: 중앙백신) trades under KRX code 072020 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is Choong ANG Vaccine Laboratory?
Its market capitalisation was US$62.5M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Choong ANG Vaccine Laboratory's latest annual revenue and operating profit?
For fiscal year 2025, Choong ANG Vaccine Laboratory reported revenue of US$37M, operating profit of US$4.9M and net income of US$4.6M, per its annual report on DART (data retrieved from DART on 2026-09-17). Revenue was up 7.6% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-17
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Operating results (preliminary) (fair disclosure)
Choong ANG Vaccine Laboratory filed provisional (unaudited) separate results for Q2 2026: revenue of US$8.37M (−1.2% year on year), operating profit of US$804K (−23.8% year on year) and net income of US$907K (+90.4% year on year).
Earnings · Aug 5 - Supply contract signed
Choong ANG Vaccine Laboratory disclosed a supply contract with the Public Procurement Service, worth US$3.87M, about 11.85% of its recent annual revenue, running through Nov 2026.
Supply contract · Jul 8 - Operating results (preliminary) (fair disclosure)
Choong ANG Vaccine Laboratory filed provisional (unaudited) separate results for Q1 2026: revenue of US$8.72M (−4.9% year on year), operating profit of US$2.07M (+31% year on year) and net income of US$2.31M (+57.6% year on year).
Earnings · May 6 - Cash/in-kind dividend decision
Choong ANG Vaccine Laboratory declared a cash dividend of US$0.14 per share.
Dividend · Feb 6 - Change of less than 30% in revenue or profit/loss structure (15% for large companies) (voluntary)
Choong ANG Vaccine Laboratory reported separate results for FY2025: revenue of US$33.4M (+7.6% year on year), operating profit of US$4.41M (+12.5% year on year) and net income of US$4.19M (−10.1% year on year).
Earnings · Feb 6